Cellectar to present Phase 2 CLOVER WaM subset efficacy data

Cellectar Biosciences says it will present Phase 2 CLOVER WaM subset efficacy data of iopofosine I 131 for patients refractory/resistant to BTK inhibitor therapy at an international workshop for Waldenström macroglobulinemia.